1979 - 1982  B.Sc., Medical Sciences, Henan Medical University

1983 - 1989  Assistant and Associate, Institute of Biophysics, Chinese Academy of Sciences

1989 - 1993  M.D., Microbiology and Immunology, Heidelberg University, Germany

1994 - 1996  Post-doc, Immunology, Memorial Sloan-Kettering Cancer Center, U.S.A

1997 -           Professor, Selected for 100 Talents Program, Chinese Academy of Sciences

2007 - 2017  Vice President & Secretary-General of Chinese Biophysical Society

2015 - 2018  President of Asian Biophysics Association

2015 -           Academician of Chinese Academy of Sciences

Dr. Yan's research group focuses on precision cancer treatment, with emphasis on studies related to selecting new targets for tumors, finding new material for drug delivery and developing new strategies to combat cancer. Dr. Yan and her research group discovered CD146 as a novel tumor target with clinical therapeutic value, identified the ligands of CD146 for the first time, studied its role in tumor development, and developed therapeutic humanized antibodies for the treatment of liver cancer, pancreatic cancer, and colon cancer. In the process of exploring new methods of tumor diagnosis and treatment, her group also discovered that iron oxide nanoparticles possess peroxidase-like activity, which was the first ever report on intrinsic enzyme-like properties of nano-materials. Subsequently, she introduced the concept of "nanozyme" and used nano-materials as enzyme mimics to create new methods for tumor diagnosis and nanozyme-strip for rapid local detection of infectious diseases such as Ebola virus. She has also established the standard for detection nanozyme catalytic activity and developed world's first nanozyme product. Her discovery of nanozymes changed the general view that nanoparticles are chemically inert and opened many new applications for nanozymes as enzyme mimics in various major fields, including medicine, agriculture, food production, biotechnology, and environmental protection. Her work has been well recognized through honors such as the National Prize for Natural Science.

Nanozyme & Ferritin:

1. Xiyun Yan, Nanozymology, Springer, 2020, ISBN 978-981-15-1489-0，ISBN 978-981-15-1490-6 (eBook)

2. Lizeng Gao, Jie Zhuang, Leng Nie, Jinbin Zhang, Yu Zhang, Ning Gu, Taihong Wang, Jing Feng, Dongling Yang, Sarah Perrett*, Xiyun Yan*. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles and application in an immunoassay. Nature Nanotechnology. 2007, 2 (9) 577.

3. Kelong Fan, Changqian Cao, Yongxin Pan, Di Lu, Dongling Yang, Jing Feng, Lina Song, Minmin Liang*, Xiyun Yan*. Magnetoferritin nanoparticles for targeting and visualizing tumor tissues. Nature Nanotechnology. 2012, 7(7), 4594.

4. Minmin Liang, Kelong Fan, Meng Zhou, Demin Duan, Jiyan Zheng, Dongling Yang, Jing Feng and Xiyun Yan*. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proceedings of the National Academy of Sciences of the United States of America. 2014,111(41) ,14900.

5. Demin Duan, Kelong Fan, Dexi Zhang, ShuguangTan, Mifang Liang, Yang Liu, Jianlin Zhang, PanheZhang, Wei Liu, Xiangguo Qiu, Gary P. Kobinger, George Fu Gao, Xiyun Yan*. Nanozyme-strip for rapid local diagnosis of Ebola. Biosensors and Bioelectronic. 2015, 74(5),134.

6. Yanzhao Zhao, Minmin Liang, Xiao Li, Kelong Fan, Jie Xiao, Yanli Li, Hongcheng Shi, Fei Wang, Hak Soo Choi*, Dengfeng Cheng*, Xiyun Yan*. Bioengineered Magnetoferritin Nanoprobes for Single-Dose Nuclear-Magnetic Resonance Tumor Imaging. ACS Nano. 2016; 10 (4), 4184-4191

7. Bing Jiang, Demin Duan, Lizeng Gao, Mengjie Zhou, Kelong Fan, Yan Tang, Juqun Xi, Yuhai Bi, Zhou Tong, George Fu Gao, Ni Xie, Aifa Tang, Guohui Nie, Minmin Liang*, Xiyun Yan*. Standardized assays for determining the catalytic activity and kinetics of peroxidase-like nanozymes. Nature Protocols. 2018

8. Kelong Fan, Juqun Xi, Lei Fan, Peixia Wang, Chunhua Zhu, Yan Tang, Xiangdong Xu, Minmin Liang, Bing Jiang, Xiyun Yan*, Lizeng Gao*. In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy. Nature Communications. 2018, 9(1), 1440.

9. Minmin Liang, Hui Tan, Jun Zhou, Tao Wang, Demin Duan, Kelong Fan, Jiuyang He, Dengfeng Cheng*, Hongcheng Shi*, Hak Soo Choi*, and Xiyun Yan*. Bioengineered H-Ferritin Nanocages for Quantitative Imaging of Vulnerable Plaques in Atherosclerosis. ACS Nano. 2018, 12(9), 9300.

10. Bolong Xu, Hui Wang, Weiwei Wang, Lizeng Gao, Shanshan Li, Xueting Pan, Hongyu Wang, Hailong Yang, Xiangqin Meng, Qiuwen Wu, Lirong Zheng, Shenming Chen, Xinghua Shi, Kelong Fan*, Xiyun Yan*, Huiyu Liu*. Single-Atom Nanozyme for Wound Antibacterial Applications. Angewandte Chemie International Edition. 2019, 10.1002/ange.201813994

11. Kelong Fan*, Xiaohua Jia, Meng Zhou, Kun Wang, Joao Conde, Jiuyang He, Jie Tian*, Xiyun Yan*. Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma. ACS Nano. 2018, 12, 4105.

12. Shuai Zhao, Hongxia Duan, Yili Yang, Xiyun Yan*, Kelong. Fenozyme Protects the Integrity of Blood Brain Barrier against Experimental Cerebral Malaria. Nano Letters. 2019, 19, 8887

13．Bing Jiang, Xuehui Chen, Guoming Sun, Xiangru Chen, Yufang Yin, Yiliang Jin, Qian Mid, Long M, Yili Yang, Xiyun Yan*, Kelong Fan*. A natural drug entry channel in the ferritin nanocage. Nano Today. 2020, 35, 100948.

14. Qian Liang, Juqun Xi, Xuejiao J. Gao, Ruofei Zhang, Yili Yang, Xingfa Gao, Xiyun Yan*, Lizeng Gao*, Kelong Fan*. A metal-free nanozyme-activated prodrug strategy for targeted tumor catalytic therapy. Nano Today. 2020, 35, 100935.

15. Zhuoran Wang, Ruofei Zhang, Xiyun Yan*, Kelong Fan*. Structure and activity of nanozymes: Inspirations for de novo design of nanozymes. Materials Today. 2020, 41, 81.

16. Xiaojing Cheng, Kelong Fan, Lin Wang, Xiangji Ying, Andrew J. Sanders, Ting Guo, Xiao fang Xing, Meng Zhou, Hong Du, Ying Hu, Huirong Ding, Ziyu Li, Xianzi Wen, Wenguo Jiang*, XiyunYan*, Jiafu Ji*. TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer. Cell Death & Disease. 2020, 11(2), 92.

CD146:

1. 段红霞, 熊朝亮, 景林, 徐庆吉, 刘晶玉, 马欣然, 王大吉, 向建全, 何志恒, 冯静*, 阎锡蕴*. CD146三十年研究的回顾与展望. 中国科学：生命科学. 2020, 50(12),1339.

2. Xiyun Yan*, Yun Lin, Dongling Yang, Yi Shen, Mei Yuan, Zhiqiang Zhang, Peiyu Li, Hongtian Xia, Li Li, Dandan Luo, Qin Liu, Karlheinz Mann, Bernhard L. Bader. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood. 2003, 102 (1), 184.

3. Yanyong Kang, Fengcai Wang, Jing Feng, Dongling Yang , Xu Yang, Xiyun Yan*. Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Research. 2006, 16, 313.

4. Qin Liu,Bairu Zhang, Xingang Zhao, Ying Zhang, Yixun Liu, Xiyun Yan*. Blockade of Adhesion Molecule CD146 Causes Pregnancy Failure in Mice. Journal of Cellular Physiology. 2015, 3, 621.

5. Tianxia Jiang, Jie Zhuang, Hongxia Duan, Yongting Luo, Qiqun Zeng, Kelong Fan, Huiwen Yan, Di Lu, Zhongde Ye, Junfeng Hao, Jing Feng, Dongling Yang, Xiyun Yan*. CD146 is a co-receptor for VEGFR-2 in tumor angiogenesis. Blood. 2012, 120 (11), 2330.

6. Zhongde Ye, Chunxia Zhang, Tao Tu, Min Sun, Dan Liu, Di Lu, Jing Feng, Dongling Yang, Feng Liu*, Xiyun Yan*. Wnt5a uses CD146 as a receptor to regulatecell motility and convergent extension. Nature Communications. 2013;4,2803.

7. Tao Tu, Chunxia Zhang, Huiwen Yan, Yongting Luo, Ruirui Kong, Pushuai Wen, Zhongde Ye, Jianan Chen, Jing Feng, Feng Liu, Jane Y. Wu*, Xiyun Yan*. CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Research. 2015, 25(3), 275.

8. Yongting Luo, Hongxia Duan, Yining Qian, Liqun Feng, Zhenzhen Wu, Jing Feng, Dongling Yang, Zhihai Qin, Xiyun Yan*. Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis. Cell Research, 2017.

9. Qian Gao, Junfeng Zhang, Xiumei Wang, Ying Liu, Rongqiao He, Xingfeng Liu, Fei Wang, Jing Feng, Dongling Yang, Zhaoqing Wang*, Anming Meng*, Xiyun Yan*. The signalling receptor MCAM coordinates apical-basal polarity and planar cell polarity during morphogenesis. Nature Communications. 2017, 7(8), 15279.

10. Jianan Chen, Yongting Luo, Hui Hui, Tanxi Cai, Hongxin Huang, Fuquan Yang, Jing Feng, Jingjing Zhang*, Xiyun Yan*. CD146 coordinates brain endothelial cell-pericyte communication for blood-brain barrier development. Proceedings of the National Academy of Sciences of the United States of America. 2017, 114(36), E7622.

11. Yongting Luo, Xiao Teng, Lingling Zhang, Jianan Chen, Zheng Liu, Xuehui Chen, Shuai Zhao, Sai Yang, Jing Feng* & Xiyun Yan*. Publisher Correction: CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nature Communications. 2019 Aug 7;10(1):3551.

12. Daji Wang, Hongxia Duan, Jing Feng, Jianquan Xiang, Liqun Feng, Dan Liu, Xuehui Chen, Lin Jing, Zheng Liu, Dexi Zhang, Hongjun Hao, Xiyun Yan. Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction. Theranostics. 2020, 10(1), 231.

13. Hongxia Duan*, Shuai Zhao, Jianquan Xiang, Chenhui Ju, Xuehui Chen, Irene Gramaglia, Xiyun Yan*. Targeting the CD146/Galectin-9 axis protects the integrity of the blood-brain barrier in experimental cerebral malaria. Cellular & Molecular Immunology. 2020, doi.org/10.1038/s41423-020-00582-8

14. Zhenzhen Wu, Jingyu Liu, Gang Chen, Junfeng Du, Huiyun Cai, Xuehui Chen, Gaoqi Ye,Yongting Luo, Yiyi Luo, Liwen Zhang, Hongxia Duan, Zheng Liu, Sai Yang, Hongwei Sun,Yan Cui, Lei Sun, Hongjie Zhang, Guizhi Shi, Taotao Wei, Pingsheng Liu, Xiyun Yan*, Jing Feng*, Pengcheng Bu*. CD146 is a Novel ANGPTL2 Receptor that Promotes Obesity by Manipulating Lipid Metabolism and Energy Expenditure. Advanced Science. 2021, doi.org/10.1002/advs.202004032

(From Xiyun Yan, February 26, 2021)